Seer (SEER) to Release Earnings on Wednesday

Seer (NASDAQ:SEER - Get Free Report) is anticipated to post its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Seer to post earnings of ($0.2926) per share and revenue of $3.40 million for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Seer (NASDAQ:SEER - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03. The business had revenue of $4.20 million during the quarter, compared to the consensus estimate of $4.60 million. Seer had a negative net margin of 443.96% and a negative return on equity of 26.04%.

Seer Stock Performance

Shares of SEER stock opened at $1.86 on Wednesday. The company has a market capitalization of $104.94 million, a price-to-earnings ratio of -1.45 and a beta of 1.63. The company has a 50-day simple moving average of $1.83 and a 200 day simple moving average of $1.91. Seer has a 52 week low of $1.65 and a 52 week high of $2.41.

Institutional Trading of Seer

Institutional investors and hedge funds have recently made changes to their positions in the company. Occudo Quantitative Strategies LP bought a new stake in shares of Seer during the 2nd quarter worth approximately $25,000. Marshall Wace LLP bought a new stake in shares of Seer during the 4th quarter worth approximately $85,000. Quadrature Capital Ltd bought a new stake in shares of Seer during the 4th quarter worth approximately $101,000. Barclays PLC lifted its holdings in shares of Seer by 685.0% during the 4th quarter. Barclays PLC now owns 60,717 shares of the company's stock worth $111,000 after acquiring an additional 52,982 shares during the period. Finally, Corient Private Wealth LLC lifted its holdings in shares of Seer by 46.3% during the 2nd quarter. Corient Private Wealth LLC now owns 63,200 shares of the company's stock worth $135,000 after acquiring an additional 20,000 shares during the period. Institutional investors own 75.20% of the company's stock.

Analyst Upgrades and Downgrades

SEER has been the subject of a number of recent research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Seer in a report on Tuesday, April 21st. TD Cowen raised shares of Seer to a "strong-buy" rating in a report on Monday, April 13th. Finally, Canaccord Genuity Group initiated coverage on shares of Seer in a report on Monday. They issued a "buy" rating and a $4.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $4.00.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer's platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company's flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.